Browse drugs

…dy included 314 anti-TNF treatment courses (212 infliximab, 102 adalimumab) in 248 patients at a tertiary centre in the United Arab Emirat…

…S-0520 Figure 3). Long-term outcomes consistently favored early infliximab therapy, with higher clinical remission rates at week 52 (57.8%…

…oprine proved ineffective in maintaining clinical remission and Infliximab was initiated. Due to ongoing symptoms her IFX dose was increas…

…faecal calprotectin (r = –0.10, p = 0.62) were not significant. Infliximab cohort: 145 patients (420 determinations), mean age 47 ± 20 yea…

… skin involvement. Only one patient required discontinuation of infliximab.Our findings suggest that paediatric IBD patients can develop a…

…even in the absence of transcriptomic reprogramming.Conclusions Infliximab response is defined by wholesale mucosal reprogramming: 694 pai…

…y clinical diagnosis).Pre-treatment FRS significantly predicted infliximab non-response (responders: -0.078±0.394 vs non-responders: 0.599…

…ngle-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rit…

…iagnosed with Crohn’s disease at age 10. Initially treated with infliximab, he was switched to adalimumab due to allergic reaction. He did…

…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…

…l surgery.Advanced therapies used for treatment of OFG included adalimumab (n=56), infliximab (n=52), ustekinumab (n=23), risankizumab (n=…

…tegy for patients with immune-mediated inflammatory diseases on infliximab maintenance therapy.Trial registration number NCT03074656.…